Asence

What Asence does

Asence is a US-incorporated pharmaceutical company, founded in 2003, that specializes in the supply of quality pharmaceutical preparations to international markets. The group operates through Asence Inc., USA (parent, headquartered in New York) and Asence Pharma Private Limited (Indian subsidiary), with cGMP-compliant API and formulation manufacturing based in Vadodara, India and commercial offices in Mumbai, Ahmedabad, and New York. Leadership has been continuous since inception under President, CEO and Director Mohal K. Sarabhai, supported by senior personnel with multi-decade Sarabhai Group tenure across QC/QA, finance, and corporate advisory functions.

The product portfolio spans four categories: bulk drugs (Active Pharmaceutical Ingredients including anticoagulants, antifungals, local anaesthetics, oncology agents, and specialty chemicals) manufactured under cGMP guidelines using both fermentation and synthetic routes; formulations (tablets, effervescent tablets, powders, injections, lyophilized injections, ointments, creams, and gels) covering analgesics, antibiotics, cardiovascular, anti-cancer, anti-epileptic, anti-diabetic, gastrointestinal, and hormonal therapeutic areas; specialty effervescent products including vitamins, immune support, cold/cough remedies, energy drinks, electrolytes, sleep aids, and prescription combinations such as Sildenafil and Tramadol; and veterinary products (probiotic feed supplements and mycotoxin binders for poultry and aquaculture). The company maintains more than 100 internationally registered products with associated Drug Master Files.

The business model is B2B sales-led, distributing pharmaceutical preparations globally through an international alliances network to enterprise buyers across North America, Asia, and Europe (with UK presence). Pricing is quote-based and not publicly disclosed. The company is privately held and family-controlled under the Sarabhai family, with affiliations to a broader Sarabhai Group ecosystem that includes Ambalal Sarabhai Enterprises, Synbiotics, Systronics, CoSara Diagnostics, Telerad India, Vovantis, Sarabhai Chemicals, and ASE.Life. No external institutional investment, public listing, or funding rounds have been identified. The company also markets consumer-facing supplement brands (LIMCEE, MAXIPLEX, Saravit C, FizziZyme, FizzCal+D3, Skyfit, Urifizz, FLUFIZZ C, SARANAC Gel) primarily for the Indian domestic market.

Name

Asence

Legal name

Asence Pharma Private Limited

Website

https://asence.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Asence is a US-incorporated, privately held pharmaceutical company (founded 2003) that manufactures Active Pharmaceutical Ingredients and Finished Dosage Forms under cGMP guidelines in India and supplies bulk drugs, formulations, effervescent products, and veterinary preparations to international markets via an alliances network, under Sarabhai family control.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industries

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Mycotoxin Risk Management (Binders, Deactivators) (AFADAKAG)

Keywords

• Active pharmaceutical ingredients
• Finished dosage formulations
• Bulk drug manufacturing
• Effervescent tablets
• Veterinary pharmaceuticals

Headquarters

HQ city

Vadodara

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Preparations Sales: Sale of Active Pharmaceutical Ingredients (Bulk Drugs) and Finished Dosage Forms (Formulations) to international markets through company's vast infrastructure of international alliances

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Asence manufactures and supplies quality pharmaceutical preparations to international markets, including Active Pharmaceutical Ingredients (Bulk Drugs) and Finished Dosage Forms (Formulations) such as tablets, effervescent tablets, powders, injections, lyophilized injections, ointments, creams, and gels. The company also produces specialty veterinary products including probiotic feed supplements and mycotoxin binders, serving pharmaceutical buyers and distributors globally.

Product overview

Asence Pharma Private Limited is a pharmaceutical company subsidiary of Asence Inc. USA, offering a diversified portfolio of pharmaceutical products organized across four main product categories: (1) Bulk Drugs - Active Pharmaceutical Ingredients manufactured in GMP-compliant plants in Vadodara, India including anticoagulants, antifungals, local anaesthetics, and oncology drugs; (2) Formulations - Finished Dosage Forms including tablets, injections, lyophilized injections, ointments, creams, and gels sold under brand names like ZID, AZISARA, HYDREA, METICA, and AMSACH across therapeutic areas including analgesics, antibiotics, anti-cancer, cardiovascular, and hormonal treatments; (3) Effervescent Products - Specialty effervescent tablets including Vitamin C, Calcium+Vitamin D, Digestive Enzymes, Energy Drinks, Sleep Aids, Cold/Cough remedies, Immune Support supplements, and prescription products like Sildenafil and Paracetamol; (4) Veterinary Products - Specialty products including Probiotic Feed Supplement (GRO UP) and Mycotoxin Binder (MEGAWIN). The company maintains operations in India (Vadodara, Mumbai, Ahmedabad) and USA (New York) with over 100 registered products internationally.

Differentiator

Problem solved

Functional benefit

Brands

• Saravit C: Vitamin supplement brand
• Skyfit
• Urifizz
• LIMCEE
• MAXIPLEX
• SARANAC Gel
• FizziZyme
• FLUFIZZ C
• FizzCal+D3

Products and services

• Active Pharmaceutical Ingredients (Bulk Drugs)
• Finished Dosage Formulations
• Effervescent Tablets Portfolio
• Veterinary Pharmaceutical Products

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Synbiotics LimitedcoreOthers · 30 July 2026Related group company within the Sarabhai Group of Companies. The company was authorized to provide loans and guarantees to Synbiotics Limited under Section 185 of the Companies Act, 2013.
• Systronics India LimitedcoreOthers · 30 July 2026Related group company within the Sarabhai Group of Companies. The company was authorized to provide loans and guarantees to Systronics India Limited under Section 185 of the Companies Act, 2013.
• Ambalal Sarabhai EnterprisescoreOthers · 30 July 2026Parent holding company that held 48th AGM on July 30, 2026, approving director reappointments and authorizing loans/guarantees to group companies.
• CoSara DiagnosticsminorOthersGroup company established in 2017 focusing on manufacturing and selling molecular diagnostics products in India and other international markets.
• Telerad IndiaminorOthersGroup company within the Sarabhai Group ecosystem
• VovantisminorOthersGroup company within the Sarabhai Group ecosystem
• Sarabhai ChemicalsminorOthersGroup company within the Sarabhai Group ecosystem
• ASE.LifeminorOthersGroup company within the Sarabhai Group ecosystem

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Alembic Pharmaceuticals: Indian manufacturer of APIs and finished formulations across similar therapeutic categories (antibiotics, cardiovascular, anti-infectives) with global export footprint. Directly comparable mid-to-large scale Indian pharma with API + formulation integration.
• Ipca Laboratories: Indian pharma manufacturer producing APIs and formulations across anti-malarial, cardiovascular, anti-diabetic, and pain management categories for global markets. Comparable in API + formulation dual model and export orientation.
• Unichem Laboratories: Indian pharmaceutical company manufacturing APIs and formulations across cardiovascular, CNS, anti-infectives with international presence. Comparable scale and business model to Asence.
• Hikal Limited: Indian API and intermediates manufacturer with cGMP-compliant facilities serving global pharma customers. Closely comparable on the API manufacturing and supply side of Asence's business.
• SMS Pharmaceuticals: Indian API manufacturer producing oncology, antifungal, and specialty APIs under cGMP for international markets. Comparable on the bulk-drug/API business vertical of Asence.
• Bal Pharma: Indian pharma company manufacturing APIs and formulations across similar therapeutic categories with export presence. Closely comparable mid-sized Indian pharma with API/formulation model.
• Panacea Biotec: Indian pharma manufacturer with portfolio in antibiotics, oncology, and specialty dosage forms including effervescent formulations. Comparable in dosage-form breadth and therapeutic coverage.
• Cadila Pharmaceuticals: Indian pharma manufacturer with API and formulation portfolio across antibiotics, cardiovascular, oncology and specialty categories. Comparable mid-sized Indian pharma manufacturer with international focus.

Regional players

• TTK Healthcare: Diversified Indian healthcare and pharma company with prescription and consumer health products. Comparable in mid-sized pharma positioning and Indian-market orientation.

Broad incumbents

• Kemin Industries: Global animal nutrition and feed additive manufacturer offering mycotoxin binders and probiotics for poultry and aquaculture. Directly comparable to Asence's MEGAWIN and GRO UP veterinary feed supplement lines.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asence